绿脓杆菌制剂辅助治疗肺癌临床研究  

A clinic study on PA-MSHA vaccine adjuvant therapy for lung cancer

作　　者：郏琴[1] 孙依萍[1] 蔡蓉[1] 王春燕[1] 俞静[1] 

机构地区：[1]上海交通大学医学院附属新华医院呼吸内科,200092

出　　处：《实用医学杂志》2007年第16期2487-2489,共3页The Journal of Practical Medicine

摘　　要：目的:评价Ⅱ类新生物制品绿脓杆菌制剂(PA-MSHA)作为免疫调节剂的有效性和安全性。方法:采用非盲法随机对照试验。试验组肺癌患者20例,对照组20例。两组采用同样的化疗方案,试验组加用绿脓杆菌制剂。治疗结束后评价疗效和感染率,并在治疗前后分别检测患者免疫功能。结果:试验组有效率(CR+PR)为65%,对照组45%(P<0.01);试验组感染率为15%,对照组为40%(P<0.05);试验组治疗后C3、C4、CD4/CD8比值、NK细胞活性和IL-2水平均高于对照组(P<0.05)。试验组中3例患者出现不良反应,均自行缓解。结论:绿脓杆菌制剂能明显提高肺癌患者的免疫功能,与化疗药物合用可提高疗效,并有预防感染作用。Objective To evaluate the effectiveness and safety of pseudomonas aeruginous MSHA （PA-MSHA） vaccine used as an immune modulator. Methods We conducted a non-blinded, randomized, controlled trial. 40 patients with lung cancer were randomly assigned to receive either chemotherapy alone （control group, n = 20） or the same therapy plus PA-MSHA vaccine （experimental group, n = 20）. Immune function was measured before and after treatment. The response rate and the infection rate were evaluated following completion of the therapy. Results The response rate （CR ＋ PR） was 65% in the experimental group and 45% in the control group （P 〈 0.01）. The infection rate was 15% in the experimental group arid 40% in the control group （P 〈 0.05）. After treatment, C3, C4, the ratio of CD4 to CDa, NK cell activity, and IL-2 level in the experimental group were significantly higher than those in the control group（P 〈 0.05）. Some adverse events occurred in 3 patients on PA-MSHA vaccine but relieved spontaneously. Conclusion PA-MSHA vaccine can evidently enhance the immune function of patients with lung cancer, protect them against infection, and improve the efficacy of chemotherapy.

关 键 词：肺肿瘤 绿脓杆菌 免疫调节剂 

分 类 号：R734.2[医药卫生—肿瘤]